Records and reported status
Jun 22, 2026 FDA drug enforcement
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit
Class II Reported ongoing
Distribution: U.S. Nationwide
Official source for DULOXETINE D/R, a) 30 mg (NDC 61919-482-30), 30 Caps; b) 30 mg (NDC 61919-482-60), 60 Caps; CYMBA... Mar 7, 2025 FDA drug enforcement
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Class II Reported ongoing
Distribution: Nationwide
Official source for Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, D... Mar 7, 2025 FDA drug enforcement
CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.
Class II Reported ongoing
Distribution: Nationwide
Official source for Duloxetine D/R, 30 mg, 30 Caps, RX Only, Packaged as a) 30-count bottle NDC 61919-0482-30, b) 60-... Jan 31, 2025 FDA drug enforcement
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
Class II Reported ongoing
Distribution: Physicians and medical facilities in 5 states: AL, CA, FL, GA, ID
Official source for CIPROFLOXACIN OPHTH SOLUTION, 0.3% 5mL bottle, Rx Only, Generic for CILOXAN, Packaged and Distrib... Aug 9, 2024 FDA drug enforcement
Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing.
Class II Reported ongoing
Distribution: Nationwide in the US
Official source for Ibuprofen 800mg, Generic for: Motrin, Each tablet contains: Ibuprofen, USP 800 mg, Packaged and D... Mar 22, 2023 FDA drug enforcement
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
Class II Reported ongoing
Distribution: Nationwide in the USA
Official source for Alprazolam C-IV, 0.5 mg, 30 Tabs per bottle, Rx only, Packaged and Distributed By: Direct Rx Daws... Mar 22, 2023 FDA drug enforcement
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
Class II Reported ongoing
Distribution: Nationwide in the USA
Official source for Alprazolam C-IV, 1 mg, packaged in a) 30 Tabs per bottle, NDC 72189-213-30; b) 60 Tabs per bottle... Mar 22, 2023 FDA drug enforcement
CGMP Deviations: Repackaging firm recalling due to potential product cross contamination concerns at the manufacturer.
Class II Reported ongoing
Distribution: Nationwide in the USA
Official source for Alprazolam C-IV, 2 mg, 60 Tabs per bottle, Rx only, Packaged and Distributed By: Direct Rx Dawson... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Montelukast Sodium Tablets, USP, 10 mg Tablets, Rx Only, Packaged as: a) 30-count bottle, NDC 619... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Finasteride, USP, 5 mg Tablets, Rx Only, Packaged as a 90-count bottle, NDC 61919-0733-90; Packag... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Ropinirole, USP, 0.25 mg Tablets, Rx Only, Packaged as a 30-count bottle, NDC 72189-0364-30; Pack... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Ropinirole, USP, 1 mg Tablets, Rx Only, Packaged as a 30-count bottle, NDC 72189-0364-30; Package... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Glimepiride, USP, 1 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0723-30; b) ... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Glimepiride, USP, 2 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0488-30; b) ... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Glimepiride, USP, 4 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0250-30; b) ... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Simvastatin, USP, 5 mg Tablets, Rx Only, Packaged as a 90-count bottle, NDC 61919-0710-90 Package... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Simvastatin, USP, 10 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0688-30 b) ... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Simvastatin, USP, 20 mg Tablets, Rx Only, Packaged as a a) 30-count bottle, NDC 61919-0446-30 b) ... Mar 13, 2023 FDA drug enforcement
cGMP deviations
Class II Reported terminated
Distribution: Nationwide in the USA
Official source for Simvastatin, USP, 40 mg, Rx Only, Packaged as a 90-count bottle, NDC 61919-0431-90, Packaged and ... Nov 2, 2022 FDA drug enforcement
cGMP deviation: discontinue of stability support for product.
Class II Reported terminated
Distribution: FL
Official source for Moxifloxacin Ophthalmic Solution, 0.5%, 3 mL, Rx Only, Packaged and Distributed By: Direct Rx, LL...
Reasons in these listed records CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit. Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle Failed Impurities/Degradation Specifications: Product failed impurity specifications at the 18-month stability testing. These examples come from this result page and are not a ranking of every recall reason.
Checking Direct Rx Is there a recall on direct rx right now? This archive contains 30 records, including 8 with agency-reported ongoing status. The status field can be incomplete or stale. Open the current official notice and match your exact product.
How do I check my package or product? Compare the product, firm and lot, date, model or serial identifiers with the notice. Use the label-check guide if you need help locating an identifier.
Does a matching name mean every item is included? A name is a search match. The agency notice sets the affected products and identifiers. Do not assume that every item with the same name or brand belongs to the recall.
What if the search finds no matching record? This search has source and keyword limits. Missing records or a missing lot code do not establish that a product is unaffected. Check source coverage and the agency's current notices.
Where can I find older records? Use monthly archives or the local search. The initial import covers records dated from October 2021 where available; each source's actual first and latest dates appear on the coverage page.